Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts’
opinion. The compromise between EBM and possibilities in healthcare

Affiliations

Maciej Banach: ORCiD; Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland
Jarosław Kaźmierczak: ORCiD; Department of Cardiology, Pomeranian Medical University, Szczecin, Poland
Przemysław Mitkowski: ORCiD; 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
Krystian Wita: ORCiD; First Department of Cardiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland
Marlena Broncel: ORCiD; Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz (MUL), Lodz, Poland
Mariusz Gąsior: ORCiD; 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Marek Gierlotka: ORCiD; Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Opole, Poland
Robert Gil: ORCiD; Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
Piotr Jankowski: ORCiD; Department of Internal Medicine and Geriatric Cardiology, Center of Postgraduate Medical Education, Warsaw, Poland
Maciej Niewada: ORCiD; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
Adam Witkowski: ORCiD; Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland

Abstract

No abstracts available.